title: The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5).
authors.forename: L
authors.initials: L
authors.lastname: Wallentin
authors.forename: R C
authors.initials: RC
authors.lastname: Becker
authors.forename: S K
authors.initials: SK
authors.lastname: James
authors.forename: R A
authors.initials: RA
authors.lastname: Harrington
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics / Q000401:mortality*; D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D026661:Clinical Trials Data Monitoring Committees; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D005060:Europe / Q000453:epidemiology; D020022:Genetic Predisposition to Disease; D006801:Humans; D012107:Research Design; D015996:Survival Rate; D000077486:Ticagrelor; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000077144:Clopidogrel; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine